Figure 3
From: PAM staining intensity of primary neuroendocrine neoplasms is a potential prognostic biomarker
Patient survival analysis according to intensity of peptidylglycine α-amidating monooxygenase (PAM) immunohistochemical reactivity in G1 and G2 primary neuroendocrine neoplasms only. Kaplan–Meier log rank test was calculated to assess the relationship between PAM staining intensity and survival for patients with G1 or G2 tumors only with PAM reactivity (< 2) and (≥ 2). Patients with reduced PAM reactivity did not have a significantly increased risk of early death (p-value = 0.12). Statistical analyses were performed using SAS Version 9.4 (SAS Institute, Cary, NC) and R.
